Cognitive Processing Slowness as a Marker of Cognitive Impairment in Non-central Nervous System Cancer Patients

Cancer is a frequent disease considering that one person out of three will be confronted with it in their lifetime. Cancer patients often express complaints related to cognitive impairment as an outcome of their oncological treatment. These cognitive disorders have a significant impact on the patient's and their carer's quality of life. Therefore, it appears necessary to have a reliable, quick and simple tool in order to detect cognitive impairment.The rationale of this study relies on 3 main points :The cognitive complaint frequently reported by cancer patientsThe difficulty in reliably demonstrating the cause of this complaint through conventional neuropsychological testsThe interest of cognitive processing speed as an indicator of cognitive dysfunctionThe primary objective of the study is to evaluate a potential variation of cognitive processing speed at the Saint-Louis Lille Battery (SSLIB) between the beginning and during (4 months after the beginning) the oncological treatment of adults with breast cancer or colon cancer.

Inclusion Criteria:Beginning an oncological treatment for breast or colon cancerPatients of age ≥ 20 and ≤ 70 years oldCancer diagnosis announcement delivered since less than 3 weeks (+/- a week)Patient affiliated to French social securityExclusion Criteria:Patient's opposition to the studyNotion of an abnormal cerebral scan or MRIDrug use (alcohol, narcotics…)Chronic (≥ 15 days) treatment with corticosteroids > 1mg/kg/j (prednisone or equivalent)Ocular pathology or cognitive disorder impairing comprehension and reading abilitiesPatients under curatorship, guardianship or under the protection of justice